Revenue: As of FY2024, the actual value is USD 607.57 K.EPS: As of FY2024, the actual value is USD -18.55, beating the estimate of USD -24.345.EBIT: As of FY2024, the actual value is USD -9.715 M, missing the estimate of USD -9.584 M.<h3>Segment Revenue</h3><ul><li>Product Revenues: $607,574 for the year ended December 31, 2024, compared to $253,573 for the year ended December 31, 2023, representing a 139.61% increase. The U.S. pharmaceutical distributor accounted for 95% of total net product sales in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Cost of Revenues: $384,765 for the year ended December 31, 2024, compared to $474,550 for the year ended December 31, 2023, representing an 18.92% decrease.</li><li>Gross Profit (Loss): $222,809 for the year ended December 31, 2024, compared to a loss of - $220,977 for the year ended December 31, 2023.</li><li>Gross Margin: 36.67% for the year ended December 31, 2024, compared to - 87.15% for the year ended December 31, 2023.</li><li>Research and Development Expenses: $4,986,526 for the year ended December 31, 2024, compared to $691,770 for the year ended December 31, 2023, representing a 620.84% increase.</li><li>General and Administrative Expenses: $5,024,985 for the year ended December 31, 2024, compared to $4,241,836 for the year ended December 31, 2023, representing an 18.46% increase.</li><li>Total Operating Expenses: $10,011,511 for the year ended December 31, 2024, compared to $4,933,606 for the year ended December 31, 2023, representing a 102.92% increase.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $5,648,088 for the year ended December 31, 2024, compared to - $4,542,910 for the year ended December 31, 2023.</li><li>Net Cash Used in Investing Activities: - $1,889,114 for the year ended December 31, 2024, compared to - $115,888 for the year ended December 31, 2023.</li><li>Net Cash Provided by Financing Activities: $7,053,571 for the year ended December 31, 2024, compared to $6,474,565 for the year ended December 31, 2023.</li></ul><h3>Unique Metrics</h3><ul><li>Research Revenues: $73,771 for the year ended December 31, 2024, compared to $0 for the year ended December 31, 2023.</li></ul><h3>Outlook / Guidance</h3><ul><li>The company plans to fund operations through third-party and related-party debt/advances, private placement of restricted securities, and issuance of stock in subsequent offerings until profitability or a business combination is achieved.</li><li>The company estimates sufficient funds to remain viable through August 31, 2025, excluding additional costs of conducting the expanded access study for chronic babesiosis patients, assuming no additional capital raises.</li></ul>

60 Degrees Pharmaceuticals | 10-K: FY2024 Revenue: USD 607.57 K